Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium
暂无分享,去创建一个
G. Giles | D. Albanes | S. Weinstein | E. Weiderpass | N. Freedman | W. Zheng | W. Blot | P. Brennan | R. Milne | Q. Cai | M. Pawlita | K. Hveem | I. Agalliu | A. Hildesheim | M. Johansson | A. Kreimer | S. Wassertheil-Smoller | M. Nygård | T. Waterboer | S. Grioni | R. Kaaks | K. Visvanathan | N. Schlecht | María-José Sánchez | H. Langseth | L. Tinker | G. D’Souza | Wen-Yi Huang | N. Bender | N. Brenner | L. Schroeder | A. Ferreiro-Iglesias | H. Robbins | E. Ness-Jensen | M. Sánchez | P. Brennan | Noemi Bender | Aida Ferreiro-Iglesias
[1] C. Kuperwasser,et al. Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV‐positive head and neck cancer , 2022, International journal of cancer.
[2] C. Fakhry,et al. Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045. , 2021, JAMA oncology.
[3] M. Guo,et al. Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. , 2021, Oral oncology.
[4] Jasmin A. Tiro,et al. Blood‐based biomarkers of human papillomavirus–associated cancers: A systematic review and meta‐analysis , 2020, Cancer.
[5] N. Allen,et al. Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank , 2020, EBioMedicine.
[6] E. Adjei Boakye,et al. Change in Age at Diagnosis of Oropharyngeal Cancer in the United States, 1975–2016 , 2020, Cancers.
[7] T. Waterboer,et al. Early Detection of Human Papillomavirus-Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal Cancer. , 2020, JAMA oncology.
[8] S. Srivastava,et al. Detection of Head and Neck Cancer Based on Longitudinal Changes in Serum Protein Abundance , 2020, Cancer Epidemiology, Biomarkers & Prevention.
[9] Jasmin A. Tiro,et al. Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. , 2020, JAMA otolaryngology-- head & neck surgery.
[10] J. Netterville,et al. Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer , 2020, Cancer.
[11] Nilanjan Chatterjee,et al. iCARE: An R package to build, validate and apply absolute risk models , 2020, PloS one.
[12] C. la Vecchia,et al. Global trends in oral and pharyngeal cancer incidence and mortality , 2020, International journal of cancer.
[13] G. Guyatt,et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study , 2019, BMJ.
[14] C. Berg,et al. Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States , 2019, Annals of Internal Medicine.
[15] E. Sturgis,et al. Projected oropharyngeal carcinoma incidence among middle‐aged US men , 2019, Head & neck.
[16] P. Pierorazio,et al. Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer , 2019, Cancer Prevention Research.
[17] A. Tjønneland,et al. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Viale,et al. Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy. , 2019, JCO precision oncology.
[19] K. Yasuda,et al. Risk of colorectal cancer for fecal immunochemistry test‐positive, average‐risk patients after a colonoscopy , 2018, Journal of gastroenterology and hepatology.
[20] P. Pharoah,et al. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer , 2018, JAMA oncology.
[21] P. Brennan,et al. Screening for human papillomavirus‐driven oropharyngeal cancer: Considerations for feasibility and strategies for research , 2018, Cancer.
[22] A. Alexeyenko,et al. Protein Expression in Tonsillar and Base of Tongue Cancer and in Relation to Human Papillomavirus (HPV) and Clinical Outcome , 2018, International journal of molecular sciences.
[23] C. Fakhry,et al. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. , 2018, Oral oncology.
[24] Nilanjan Chatterjee,et al. iCARE: R package to build, validate and apply absolute risk models , 2016, bioRxiv.
[25] T. McNeel,et al. Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] R. Pfeiffer,et al. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence , 2017, Cancer.
[27] R. Carrau,et al. Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base. , 2017, Oral oncology.
[28] M. Schiffman,et al. Mixture models for undiagnosed prevalent disease and interval‐censored incident disease: applications to a cohort assembled from electronic health records , 2017, Statistics in medicine.
[29] A. King,et al. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer , 2017, The New England journal of medicine.
[30] N. Freedman,et al. Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer , 2017, Journal of the National Cancer Institute.
[31] M. Wiesenfarth,et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16‐driven oropharyngeal squamous cell carcinoma , 2017, International journal of cancer.
[32] C. von Buchwald,et al. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. , 2017, European journal of cancer.
[33] Martin Eklund,et al. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial , 2017, Journal of the National Cancer Institute.
[34] M. Goodman,et al. Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. , 2016, JAMA oncology.
[35] R. Ferris,et al. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. , 2016, Cancer epidemiology.
[36] A. Blackford,et al. Rising population of survivors of oral squamous cell cancer in the United States , 2016, Cancer.
[37] Jennifer J. Hu,et al. Risk Stratification System for Oral Cancer Screening , 2016, Cancer Prevention Research.
[38] N. Aygun,et al. Visualization of the Oropharynx With Transcervical Ultrasound. , 2015, AJR. American journal of roentgenology.
[39] F. Clavel-Chapelon,et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[41] Gypsyamber D'Souza,et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Psyrri,et al. HPV and head and neck cancers: state-of-the-science. , 2014, Oral oncology.
[43] Paolo Vineis,et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] D. Altman,et al. The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.
[45] Esther Kim,et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] P. Prorok,et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. , 2007, American journal of epidemiology.
[47] Markus F Templin,et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.
[48] V. Caron,et al. United states. , 2018, Nursing standard (Royal College of Nursing (Great Britain) : 1987).